Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Share-based Compensation: 2020-2024

Historic Share-based Compensation for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $28.9 million.

  • Tango Therapeutics' Share-based Compensation fell 7.70% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.9 million, marking a year-over-year increase of 6.07%. This contributed to the annual value of $28.9 million for FY2024, which is 51.46% up from last year.
  • Latest data reveals that Tango Therapeutics reported Share-based Compensation of $28.9 million as of FY2024, which was up 51.46% from $19.1 million recorded in FY2023.
  • Tango Therapeutics' Share-based Compensation's 5-year high stood at $28.9 million during FY2024, with a 5-year trough of $1.8 million in FY2020.
  • For the 3-year period, Tango Therapeutics' Share-based Compensation averaged around $20.7 million, with its median value being $19.1 million (2023).
  • Data for Tango Therapeutics' Share-based Compensation shows a peak YoY soared of 344.05% (in 2021) over the last 5 years.
  • Over the past 5 years, Tango Therapeutics' Share-based Compensation (Yearly) stood at $1.8 million in 2020, then skyrocketed by 344.05% to $7.8 million in 2021, then skyrocketed by 81.67% to $14.2 million in 2022, then soared by 34.08% to $19.1 million in 2023, then spiked by 51.46% to $28.9 million in 2024.